These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 33852036

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Imaging artifacts of Onyx and PHIL on conventional CT, cone-beam CT and MRI in an animal model.
    Vollherbst DF, Otto R, Do T, Kauczor HU, Bendszus M, Sommer CM, Möhlenbruch MA.
    Interv Neuroradiol; 2018 Dec; 24(6):693-701. PubMed ID: 29973083
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The impact of software-based metal artifact reduction on the liquid embolic agent Onyx in cone-beam CT: a systematic in vitro and in vivo study.
    Schmitt N, Weyland CS, Wucherpfennig L, Sommer CM, Bendszus M, Möhlenbruch MA, Vollherbst DF.
    J Neurointerv Surg; 2022 Aug; 14(8):832-836. PubMed ID: 34433643
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Iterative Metal Artifact Reduction (iMAR) of the Non-adhesive Liquid Embolic Agent Onyx in Computed Tomography : An Experimental Study.
    Schmitt N, Weyland CS, Wucherpfennig L, Herweh C, Bendszus M, Möhlenbruch MA, Vollherbst DF.
    Clin Neuroradiol; 2022 Sep; 32(3):695-703. PubMed ID: 34643742
    [Abstract] [Full Text] [Related]

  • 8. Visibility of liquid embolic agents in fluoroscopy: a systematic in vitro study.
    Schmitt N, Wucherpfennig L, Hohenstatt S, Weyland CS, Sommer CM, Bendszus M, Möhlenbruch MA, Vollherbst DF.
    J Neurointerv Surg; 2023 Jun; 15(6):594-599. PubMed ID: 35508379
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Embolization of Intracranial Dural Arteriovenous Fistulas Using PHIL Liquid Embolic Agent in 26 Patients: A Multicenter Study.
    Lamin S, Chew HS, Chavda S, Thomas A, Piano M, Quilici L, Pero G, Holtmannspolter M, Cronqvist ME, Casasco A, Guimaraens L, Paul L, Gil Garcia A, Aleu A, Chapot R.
    AJNR Am J Neuroradiol; 2017 Jan; 38(1):127-131. PubMed ID: 27932510
    [Abstract] [Full Text] [Related]

  • 12. Time-of-flight magnetic resonance angiography imaging of a residual arteriovenous malformation nidus after Onyx embolization for stereotactic radiosurgery planning. Technical note.
    Loy DN, Rich KM, Simpson J, Dorward I, Santanam L, Derdeyn CP.
    Neurosurg Focus; 2009 May; 26(5):E13. PubMed ID: 19408991
    [Abstract] [Full Text] [Related]

  • 13. Quantification of tantalum sedimentation rates in liquid embolic agents.
    Mason JR, Dodge C, Benndorf G.
    Interv Neuroradiol; 2018 Oct; 24(5):574-579. PubMed ID: 29781371
    [Abstract] [Full Text] [Related]

  • 14. Embolization of peripheral arteriovenous malformations and fistulas with precipitating hydrophobic injectable liquid (PHIL®).
    Giurazza F, Corvino F, Silvestre M, Cangiano G, De Magistris G, Cavaglià E, Amodio F, Niola R.
    Radiol Med; 2021 Mar; 126(3):474-483. PubMed ID: 32889705
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of a novel liquid embolic agent (precipitating hydrophobic injectable liquid (PHIL)) in an animal endovascular embolization model.
    Vollherbst DF, Otto R, von Deimling A, Pfaff J, Ulfert C, Kauczor HU, Bendszus M, Sommer CM, Möhlenbruch MA.
    J Neurointerv Surg; 2018 Mar; 10(3):268-274. PubMed ID: 28689184
    [Abstract] [Full Text] [Related]

  • 16. Effect of liquid embolic agents on Gamma Knife surgery dosimetry for arteriovenous malformations. Clinical article.
    Mamalui-Hunter M, Jiang T, Rich KM, Derdeyn CP, Drzymala RE.
    J Neurosurg; 2011 Aug; 115(2):364-70. PubMed ID: 21495824
    [Abstract] [Full Text] [Related]

  • 17. Combined treatment approach to cerebral arteriovenous malformation in pediatric patients: stereotactic radiosurgery to partially Onyx-embolized AVM.
    Umansky D, Corn BW, Strauss I, Shtraus N, Constantini S, Frolov V, Maimon S, Kanner AA.
    Childs Nerv Syst; 2018 Nov; 34(11):2269-2274. PubMed ID: 29882061
    [Abstract] [Full Text] [Related]

  • 18. Neurological morbidity and mortality associated with the endovascular treatment of cerebral arteriovenous malformations before and during the Onyx era.
    Crowley RW, Ducruet AF, Kalani MY, Kim LJ, Albuquerque FC, McDougall CG.
    J Neurosurg; 2015 Jun; 122(6):1492-7. PubMed ID: 25816081
    [Abstract] [Full Text] [Related]

  • 19. Combined therapy of cerebral arteriovenous malformations: histological differences between a non-adhesive liquid embolic agent and n-butyl 2-cyanoacrylate (NBCA).
    Duffner F, Ritz R, Bornemann A, Freudenstein D, Wiendl H, Siekmann R.
    Clin Neuropathol; 2002 Jun; 21(1):13-7. PubMed ID: 11846039
    [Abstract] [Full Text] [Related]

  • 20. Dosimetric effects of Onyx embolization on Gamma Knife arteriovenous malformation dose distributions.
    Schlesinger DJ, Nordström H, Lundin A, Xu Z, Sheehan JP.
    J Neurosurg; 2016 Dec; 125(Suppl 1):114-122. PubMed ID: 27903195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.